Seeking Alpha

Vanda's (VNDA) tasimelteon fails its Phase IIb/III trial in the treatment of MDD (major...

Vanda's (VNDA) tasimelteon fails its Phase IIb/III trial in the treatment of MDD (major depressive disorder). VNDA says it will continue to pursue tasimelteon as a treatment for blind people with Non-24-Hour Disorder. (PR)
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector

Next headline on your portfolio:

|